Back to top
more

Ionis Pharmaceuticals (IONS)

(Delayed Data from NSDQ)

$41.05 USD

41.05
2,741,662

+0.36 (0.88%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $41.06 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Earnings Preview: Ionis Pharmaceuticals (IONS) Q1 Earnings Expected to Decline

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group

by Zacks Equity Research

Zacks.com featured highlights include: Ionis Pharmaceuticals, Aphria, Tabula Rasa Healthcare, InterDigital and Huron Consulting Group

Sanghamitra Saha headshot

Grab 5 Top Stocks With Strong Earnings Beat Prospects

by Sanghamitra Saha

Invest in top-ranked stocks that are likely to beat their earnings estimates in the upcoming releases.

Zacks Equity Research

Why Ionis Pharmaceuticals (IONS) Stock Might be a Great Pick

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Zacks Equity Research

Alnylam's Givlaari Gets Approval in Europe for Rare Disease

by Zacks Equity Research

Alnylam's (ALNY) second RNAi-based therapeutics, Givlaari receives approval in Europe for treating acute hepatic porphyria, becoming the first and only approved therapy for the indication.

Zacks Equity Research

GRFS or IONS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GRFS vs. IONS: Which Stock Is the Better Value Option?

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 40.66% and 21.72%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pfizer's Cardiomyopathy Drug Vyndaqel Gets Approval in Europe

by Zacks Equity Research

Pfizer's (PFE) Vyndaqel gets approval in Europe and becomes the first therapy approved to treat ATTR-CM in the continent.

Zacks Equity Research

ProQR (PRQR) Begins Dosing in Phase I/II Eye Disorder Study

by Zacks Equity Research

ProQR (PRQR) doses the first patient in the phase I/II Aurora study on QR-1123, which is being evaluated for treating patients with autosomal dominant retinitis pigmentosa.

Zacks Equity Research

Surging Earnings Estimates Signal Upside for Ionis Pharmaceuticals (IONS) Stock

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 158.06% and 11.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Ionis Pharmaceuticals Enters Oversold Territory

by Zacks Equity Research

Ionis Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Zacks Equity Research

Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates

by Zacks Equity Research

Key highlights of the past week include label expansion of drugs, licensing deals and more.

Zacks Equity Research

Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN

by Zacks Equity Research

Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.

Zacks Equity Research

Biogen's New Study to Test Higher Dose of SMA Drug Spinraza

by Zacks Equity Research

Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.

Zacks Equity Research

Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo

by Zacks Equity Research

Ionis (IONS) out-licenses antisense medicines to Glaxo for treating chronic hepatitis B virus infection. Glaxo exercises its option to in-license the same. Shares fall.

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 96.30% and 16.49%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 113.95% and 3.27%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More

by Zacks Equity Research

Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: What to Know Ahead of Q1 Release

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Alteryx, CommScope, Ionis Pharmaceuticals and Apache

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alteryx, CommScope, Ionis Pharmaceuticals and Apache